Ownership and insider activity for Edesa Biotech, Inc. (EDSA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate.
Price
| Price | $3.87 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-01 | Nijhawan Pardeep | A-Award | 5,714 | |
| 2026-08-03 | Nijhawan Pardeep | A-Award | 5,324 | |
| 2026-07-02 | Nijhawan Pardeep | A-Award | 3,378 | |
| 2026-06-16 | Nijhawan Pardeep | A-Award | 153,550 | |
| 2026-06-01 | Nijhawan Pardeep | A-Award | 1,671 | |
| 2026-05-27 | Marshall Patrick | A-Award | 19,000 | |
| 2026-05-27 | MacDonald Sean Arthur | A-Award | 19,000 | |
| 2026-05-27 | Chypyha Joan | A-Award | 19,000 | |
| 2026-05-27 | Weiler Peter J. | A-Award | 64,609 | |
| 2026-05-27 | Brooks Michael J | A-Award | 64,609 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.4M | $4.6M | $4.2M | $5.0M | $7.2M | $7.8M | $7.1M | $5.4M | $1.0M | $10.8M |
| Short-term Investments | $4.0M | $2.0M | $6.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $85813 | $1287 | $41246 | $217101 | $87446 | $3.3M | $1.3M | $626543 | $270908 | $642866 |
| Inventory | $249430 | $68114 | $224267 | -$217101 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $12.1M | $6.8M | $10.7M | $5.6M | $8.1M | $12.1M | $9.1M | $6.4M | $1.7M | $11.5M |
| Property, Plant & Equipment | $756114 | $879523 | $1.1M | $73058 | $174821 | $111560 | $31159 | $100075 | $18361 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $2.5M | $2.4M | $2.3M | $2.2M | $2.1M | $2.0M |
| Total Assets | $12.9M | $7.7M | $11.8M | $5.7M | $10.8M | $14.6M | $11.6M | $8.9M | $3.8M | $13.5M |
| Accounts Payable | $623644 | $320947 | $493385 | $424634 | $1.5M | $1.4M | $2.1M | $1.7M | 0 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | $69730 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $623644 | $320947 | $493385 | $461634 | $1.5M | $1.5M | $2.1M | $1.8M | $1.8M | $1.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $623644 | $320947 | $493385 | $461634 | $1.7M | $1.5M | $2.2M | $1.8M | $1.8M | $1.1M |
| Retained Earnings | -$40.4M | -$45.4M | -$50.4M | -$6.7M | -$13.1M | -$26.5M | -$44.0M | -$52.4M | -$58.6M | -$65.9M |
| Total Equity | $12.3M | $7.4M | $11.3M | $5.3M | $9.1M | $13.1M | $9.4M | $7.0M | $2.0M | $12.5M |
| Total Debt | 0 | 0 | 0 | 0 | $164189 | $99320 | $18975 | $94487 | $19867 | 0 |
| Net Debt | -$11.4M | -$6.6M | -$10.3M | -$5.0M | -$7.0M | -$7.7M | -$7.1M | -$5.3M | -$1.0M | -$10.8M |
| Working Capital | $11.5M | $6.4M | $10.2M | $5.2M | $6.6M | $10.6M | $7.0M | $4.6M | -$157205 | $10.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.76 |
Profitability
| Return on Equity | -124.21% |
| Return on Invested Capital | -166.02% |
| Return on Assets | -110.85% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BRTX · COCP · DWTX · ERNA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of EDSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks